Certaines complications peuvent être gérées, mais d'autres peuvent être irréversibles selon la gravité.
RéversibilitéGestionGravité
#3
Comment les complications affectent-elles la qualité de vie ?
Les complications peuvent réduire la qualité de vie en limitant les capacités fonctionnelles.
Qualité de vieCapacités fonctionnellesComplications
#4
Y a-t-il des risques de complications à long terme ?
Oui, des risques de complications à long terme existent, notamment des cancers et des maladies chroniques.
RisquesComplications à long termeMaladies chroniques
#5
Les complications peuvent-elles être prévenues ?
Certaines complications peuvent être prévenues par un suivi médical régulier et des interventions précoces.
PréventionSuivi médicalInterventions
Facteurs de risque
5
#1
Quels sont les facteurs de risque pour les anomalies de polyadénylation ?
Les facteurs incluent des mutations génétiques, des expositions environnementales et des infections.
Facteurs de risqueMutations génétiquesInfections
#2
L'âge est-il un facteur de risque ?
Oui, l'âge avancé peut augmenter le risque de mutations affectant la polyadénylation.
ÂgeMutationsRisque
#3
Les habitudes de vie influencent-elles la polyadénylation ?
Des habitudes comme le tabagisme et l'alcoolisme peuvent affecter les mécanismes de polyadénylation.
Habitudes de vieTabagismeAlcoolisme
#4
Les maladies chroniques augmentent-elles les risques ?
Oui, certaines maladies chroniques peuvent prédisposer à des anomalies de polyadénylation.
Maladies chroniquesPrédispositionAnomalies
#5
Les facteurs génétiques jouent-ils un rôle ?
Oui, des antécédents familiaux de maladies peuvent augmenter le risque d'anomalies de polyadénylation.
Facteurs génétiquesAntécédents familiauxRisque
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Signaux de polyadénylation : Questions médicales les plus fréquentes",
"headline": "Signaux de polyadénylation : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Signaux de polyadénylation : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-07-02",
"dateModified": "2025-03-29",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Signaux de polyadénylation"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Composants de gène",
"url": "https://questionsmedicales.fr/mesh/D040461",
"about": {
"@type": "MedicalCondition",
"name": "Composants de gène",
"code": {
"@type": "MedicalCode",
"code": "D040461",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "G05.360.340.024.340.137"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Signaux de polyadénylation",
"alternateName": "RNA 3' Polyadenylation Signals",
"code": {
"@type": "MedicalCode",
"code": "D039104",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Xiaohui Wu",
"url": "https://questionsmedicales.fr/author/Xiaohui%20Wu",
"affiliation": {
"@type": "Organization",
"name": "Department of Automation, Xiamen University, Xiamen, China."
}
},
{
"@type": "Person",
"name": "Guoli Ji",
"url": "https://questionsmedicales.fr/author/Guoli%20Ji",
"affiliation": {
"@type": "Organization",
"name": "Department of Automation, Xiamen University, Xiamen, China."
}
},
{
"@type": "Person",
"name": "Congting Ye",
"url": "https://questionsmedicales.fr/author/Congting%20Ye",
"affiliation": {
"@type": "Organization",
"name": "National Institute for Data Science in Health and Medicine, Xiamen University, Xiamen, China."
}
},
{
"@type": "Person",
"name": "Bin Tian",
"url": "https://questionsmedicales.fr/author/Bin%20Tian",
"affiliation": {
"@type": "Organization",
"name": "Gene Expression and Regulation Program, The Wistar Institute, Philadelphia, PA 19104, USA."
}
},
{
"@type": "Person",
"name": "Mihaela Zavolan",
"url": "https://questionsmedicales.fr/author/Mihaela%20Zavolan",
"affiliation": {
"@type": "Organization",
"name": "Computational and Systems Biology, Biozentrum, University of Basel, Spitalstrasse 41, 4056 Basel, Switzerland."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Helicobacter pylori and cardiovascular risk: Only a dead Helicobacter is a good Helicobacter?",
"datePublished": "2022-08-31",
"url": "https://questionsmedicales.fr/article/36046921",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1111/hel.12928"
}
},
{
"@type": "ScholarlyArticle",
"name": "Triple-drug combination therapy versus six-month proton pump inhibitor monotherapy in non-Helicobacter pylori Helicobacter eradication, and hyperacid environment preference of Helicobacter suis: a clinical study.",
"datePublished": "2024-05-08",
"url": "https://questionsmedicales.fr/article/38720287",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1186/s12876-024-03252-5"
}
},
{
"@type": "ScholarlyArticle",
"name": "The complex immunological role of Helicobacter in modulating cancer.",
"datePublished": "2022-08-27",
"url": "https://questionsmedicales.fr/article/36041951",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.it.2022.08.002"
}
},
{
"@type": "ScholarlyArticle",
"name": "Bibliometric analysis of Helicobacter pylori resistance-from 2002 to 2022.",
"datePublished": "2023-04-27",
"url": "https://questionsmedicales.fr/article/37102470",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1111/hel.12983"
}
},
{
"@type": "ScholarlyArticle",
"name": "Presence of Helicobacter cinaedi in Atherosclerotic Abdominal Aortic Aneurysmal Wall.",
"datePublished": "2023-06-15",
"url": "https://questionsmedicales.fr/article/37316278",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1620/tjem.2023.J049"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Phénomènes génétiques",
"item": "https://questionsmedicales.fr/mesh/D055614"
},
{
"@type": "ListItem",
"position": 3,
"name": "Structures génétiques",
"item": "https://questionsmedicales.fr/mesh/D040342"
},
{
"@type": "ListItem",
"position": 4,
"name": "Génome",
"item": "https://questionsmedicales.fr/mesh/D016678"
},
{
"@type": "ListItem",
"position": 5,
"name": "Composants de génome",
"item": "https://questionsmedicales.fr/mesh/D040481"
},
{
"@type": "ListItem",
"position": 6,
"name": "Gènes",
"item": "https://questionsmedicales.fr/mesh/D005796"
},
{
"@type": "ListItem",
"position": 7,
"name": "Composants de gène",
"item": "https://questionsmedicales.fr/mesh/D040461"
},
{
"@type": "ListItem",
"position": 8,
"name": "Signaux de polyadénylation",
"item": "https://questionsmedicales.fr/mesh/D039104"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Signaux de polyadénylation - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Signaux de polyadénylation",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-02",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Signaux de polyadénylation",
"description": "Comment identifier les signaux de polyadénylation ?\nQuels tests sont utilisés pour étudier la polyadénylation ?\nLes signaux de polyadénylation sont-ils visibles sur des gels ?\nPeut-on détecter des anomalies dans la polyadénylation ?\nQuels marqueurs indiquent une polyadénylation efficace ?",
"url": "https://questionsmedicales.fr/mesh/D039104?mesh_terms=Helicobacter#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Signaux de polyadénylation",
"description": "Quels symptômes sont liés à des défauts de polyadénylation ?\nLes maladies génétiques sont-elles liées à la polyadénylation ?\nComment la polyadénylation affecte-t-elle le cancer ?\nY a-t-il des symptômes associés à des ARNm instables ?\nLes infections virales affectent-elles la polyadénylation ?",
"url": "https://questionsmedicales.fr/mesh/D039104?mesh_terms=Helicobacter#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Signaux de polyadénylation",
"description": "Peut-on prévenir les anomalies de polyadénylation ?\nQuel rôle joue l'alimentation dans la polyadénylation ?\nLes facteurs environnementaux affectent-ils la polyadénylation ?\nComment le stress oxydatif influence-t-il la polyadénylation ?\nLes vaccinations influencent-elles la polyadénylation ?",
"url": "https://questionsmedicales.fr/mesh/D039104?mesh_terms=Helicobacter#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Signaux de polyadénylation",
"description": "Existe-t-il des traitements pour les anomalies de polyadénylation ?\nComment les médicaments peuvent-ils influencer la polyadénylation ?\nLes thérapies ciblées peuvent-elles aider ?\nY a-t-il des approches expérimentales en cours ?\nLes suppléments nutritionnels peuvent-ils aider ?",
"url": "https://questionsmedicales.fr/mesh/D039104?mesh_terms=Helicobacter#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Signaux de polyadénylation",
"description": "Quelles complications peuvent survenir avec des défauts de polyadénylation ?\nLes complications sont-elles réversibles ?\nComment les complications affectent-elles la qualité de vie ?\nY a-t-il des risques de complications à long terme ?\nLes complications peuvent-elles être prévenues ?",
"url": "https://questionsmedicales.fr/mesh/D039104?mesh_terms=Helicobacter#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Signaux de polyadénylation",
"description": "Quels sont les facteurs de risque pour les anomalies de polyadénylation ?\nL'âge est-il un facteur de risque ?\nLes habitudes de vie influencent-elles la polyadénylation ?\nLes maladies chroniques augmentent-elles les risques ?\nLes facteurs génétiques jouent-ils un rôle ?",
"url": "https://questionsmedicales.fr/mesh/D039104?mesh_terms=Helicobacter#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment identifier les signaux de polyadénylation ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'analyse bioinformatique et les séquençages d'ARN permettent d'identifier ces signaux."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour étudier la polyadénylation ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les tests RT-PCR et Northern blot sont couramment utilisés pour étudier la polyadénylation."
}
},
{
"@type": "Question",
"name": "Les signaux de polyadénylation sont-ils visibles sur des gels ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les produits de polyadénylation peuvent être visualisés sur des gels d'agarose après électrophorèse."
}
},
{
"@type": "Question",
"name": "Peut-on détecter des anomalies dans la polyadénylation ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des anomalies peuvent être détectées par des variations dans la taille des ARNm sur des gels."
}
},
{
"@type": "Question",
"name": "Quels marqueurs indiquent une polyadénylation efficace ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "La présence d'une queue poly-A et la stabilité de l'ARNm sont des marqueurs d'efficacité."
}
},
{
"@type": "Question",
"name": "Quels symptômes sont liés à des défauts de polyadénylation ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des défauts peuvent entraîner une instabilité de l'ARNm, affectant la synthèse protéique."
}
},
{
"@type": "Question",
"name": "Les maladies génétiques sont-elles liées à la polyadénylation ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certaines maladies génétiques peuvent résulter de mutations affectant les signaux de polyadénylation."
}
},
{
"@type": "Question",
"name": "Comment la polyadénylation affecte-t-elle le cancer ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des altérations dans la polyadénylation peuvent conduire à une expression aberrante de gènes oncogènes."
}
},
{
"@type": "Question",
"name": "Y a-t-il des symptômes associés à des ARNm instables ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des ARNm instables peuvent entraîner des troubles métaboliques et des anomalies cellulaires."
}
},
{
"@type": "Question",
"name": "Les infections virales affectent-elles la polyadénylation ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines infections virales peuvent perturber les signaux de polyadénylation, affectant l'hôte."
}
},
{
"@type": "Question",
"name": "Peut-on prévenir les anomalies de polyadénylation ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "La prévention passe par une bonne santé génétique et des dépistages précoces des maladies."
}
},
{
"@type": "Question",
"name": "Quel rôle joue l'alimentation dans la polyadénylation ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une alimentation équilibrée peut influencer positivement la régulation des gènes liés à la polyadénylation."
}
},
{
"@type": "Question",
"name": "Les facteurs environnementaux affectent-ils la polyadénylation ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des facteurs comme les toxines peuvent perturber les mécanismes de polyadénylation."
}
},
{
"@type": "Question",
"name": "Comment le stress oxydatif influence-t-il la polyadénylation ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le stress oxydatif peut endommager l'ADN et affecter les signaux de polyadénylation."
}
},
{
"@type": "Question",
"name": "Les vaccinations influencent-elles la polyadénylation ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines recherches suggèrent que les vaccinations peuvent moduler l'expression des gènes liés."
}
},
{
"@type": "Question",
"name": "Existe-t-il des traitements pour les anomalies de polyadénylation ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Actuellement, il n'existe pas de traitements spécifiques, mais des thérapies géniques sont explorées."
}
},
{
"@type": "Question",
"name": "Comment les médicaments peuvent-ils influencer la polyadénylation ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certains médicaments peuvent moduler l'expression des gènes impliqués dans la polyadénylation."
}
},
{
"@type": "Question",
"name": "Les thérapies ciblées peuvent-elles aider ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les thérapies ciblées peuvent potentiellement corriger les défauts de polyadénylation."
}
},
{
"@type": "Question",
"name": "Y a-t-il des approches expérimentales en cours ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des recherches sur des inhibiteurs spécifiques de la polyadénylation sont en cours dans des modèles précliniques."
}
},
{
"@type": "Question",
"name": "Les suppléments nutritionnels peuvent-ils aider ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines études suggèrent que des nutriments spécifiques pourraient soutenir la polyadénylation."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec des défauts de polyadénylation ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des complications incluent des troubles métaboliques, des cancers et des maladies neurodégénératives."
}
},
{
"@type": "Question",
"name": "Les complications sont-elles réversibles ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines complications peuvent être gérées, mais d'autres peuvent être irréversibles selon la gravité."
}
},
{
"@type": "Question",
"name": "Comment les complications affectent-elles la qualité de vie ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications peuvent réduire la qualité de vie en limitant les capacités fonctionnelles."
}
},
{
"@type": "Question",
"name": "Y a-t-il des risques de complications à long terme ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des risques de complications à long terme existent, notamment des cancers et des maladies chroniques."
}
},
{
"@type": "Question",
"name": "Les complications peuvent-elles être prévenues ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines complications peuvent être prévenues par un suivi médical régulier et des interventions précoces."
}
},
{
"@type": "Question",
"name": "Quels sont les facteurs de risque pour les anomalies de polyadénylation ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs incluent des mutations génétiques, des expositions environnementales et des infections."
}
},
{
"@type": "Question",
"name": "L'âge est-il un facteur de risque ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'âge avancé peut augmenter le risque de mutations affectant la polyadénylation."
}
},
{
"@type": "Question",
"name": "Les habitudes de vie influencent-elles la polyadénylation ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des habitudes comme le tabagisme et l'alcoolisme peuvent affecter les mécanismes de polyadénylation."
}
},
{
"@type": "Question",
"name": "Les maladies chroniques augmentent-elles les risques ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certaines maladies chroniques peuvent prédisposer à des anomalies de polyadénylation."
}
},
{
"@type": "Question",
"name": "Les facteurs génétiques jouent-ils un rôle ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des antécédents familiaux de maladies peuvent augmenter le risque d'anomalies de polyadénylation."
}
}
]
}
]
}
National Institute for Data Science in Health and Medicine, Xiamen University, Xiamen, China.
Key Laboratory of the Ministry of Education for Coastal and Wetland Ecosystems, College of the Environment and Ecology, Xiamen University, Xiamen, China.
Department of Biochemistry and Biophysics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA; Graduate Group in Genomics and Computational Biology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
Division of Computational Biomedicine, Department of Biological Chemistry, School of Medicine, University of California, Irvine, CA, United States. Electronic address: wei.li@uci.edu.
Helicobacter pylori (H. pylori) and cardiovascular (CV) disease share common symptoms and underlie many general medical complaints. Preliminary studies suggest an association between H. pylori positiv...
We included 3284 asymptomatic participants of a colorectal cancer screening cohort who were offered and underwent upper gastrointestinal endoscopy. We calculated the 10-year risk for a CV event using ...
In total, 2659 patients were H. pylori negative and 625 H. pylori positive. Helicobacter pylori positivity was associated with SCORE2 and remained so (r = .33; 95% CI 0.09-0.57; p = .006) after adjust...
In our study, H. pylori positivity and CV risk were independently associated. This did not translate into a dissimilar CV mortality between H. pylori positive and H. pylori negative patients. However,...
At present, eradication regimens for non-Helicobacter pylori Helicobacter (NHPH) have not been established yet. We investigated effectiveness of the standard triple-drug combination therapy for Helico...
Subjects were the patients who were diagnosed with NHPH-infected gastritis based on microscopic findings, helical-shaped organisms obviously larger than Helicobacter pylori, in the gastric mucosal spe...
PCR analysis detected NHPH in 38 patients: 36 as Helicobacter suis and two as Helicobacter heilmannii/Helicobacter ailurogastricus. Fourteen Helicobacter suis-infected and one Helicobacter heilmannii/...
In NHPH eradication, the triple-drug combination therapy was considered to be effective to some extent and to become the first-line therapy. While, although less successful, PPI monotherapy appeared t...
This study was approved by the Research Ethics Committee of Kenwakai Hospital (No. 2,017,024)....
The gut microbiota has recently emerged as a unique mechanism of immunotherapeutic resistance or response within certain cancer patients. Certain adherent bacterial species that reside along the epith...
Drug resistance in Helicobacter pylori severely affects the efficacy of eradication therapy, and a number of studies have been conducted on this issue. The aim of this study was to assess the progress...
Publications related to H. pylori resistance from 2002 to 2022 were retrieved from the Web of Science database. Relevant information including titles, authors, countries, and keywords was extracted, a...
From 2002 to 2022 (as of 09/24/2022), the field of H. pylori-resistance research produced a total of 2677 publications with a total of 75217 citations, with an overall upward trend in the annual numbe...
H. pylori-resistance research has become a popular research field, and although there are significant contributions from Europe, the United States, and East Asia, there are significant imbalances betw...
Recently, the relationship between Helicobacter cinaedi (H. cinaedi) infection and several diseases, including cardiovascular and central nervous system disorders, bone and soft tissue disorders, and ...
Helicobacter pylori bacteremia is rare and difficult to make a definite diagnosis....
This is a 40-year-old woman represented as fever and unconsciousness accompanied by tics. She was diagnosed as Helicobacter pylori bacteremia and received emergency endotracheal intubation and antibio...
Helicobacter pylori bacteremia is rare and hard to identify. Varied clinical manifestations leading to more difficult to make a definite diagnosis....
Helicobacter cinaedi is known to cause invasive infections in immunocompromised adults. Here we report the first case of H. cinaedi bacteremia in a child with nephrotic syndrome. The patient presented...
Autosomal recessive agammaglobulinemia is a severe primary antibody deficiency disorder typically presenting in infancy. We present a rare case of an 8-year-old boy with AR agammaglobulinemia due to a...
Helicobacter bilis, an enterohepatic Helicobacter species, represents a carcinogenic risk factor for cholangiocytes owing to the prevalence of infections in patients with biliary tract cancer, cholecy...
Helicobacter bilis and MMNK-1 cells were cocultured for 24 h and inflammatory cytokine secretion was evaluated. Furthermore, MMNK-1 cell proliferation, intracellular reactive oxidant species (ROS) pro...
Interleukin (IL)-6 and IL-8 secretion were significantly increased in MMNK-1 cocultures with H. bilis (IL-6, 24.3 ± 12.2 vs. 271.1 ± 286.4 pg/ml; IL-8, 167.6 ± 78.7 vs. 1085.1 ± 1047.1 pg/ml, p < .05)...
Helicobacter bilis infection induced ROS production in and enhanced the proliferation of cholangiocytes....
Recently, numerous publications on Helicobacter pylori (H. pylori) have been published, but bibliometric analyses on this research field are scarce. To address this gap, we conducted a bibliometric an...
Publications on H. pylori from 2002 to 2021 were retrieved from the Web of Science Core Collection database (WoSCC). Trends in publications and citations were analyzed using Excel 2021. VOSviewer and ...
36,266 publications on H. pylori were retrieved from the WoSCC database. In general, we observed an increasing trend in the number of publications over the past 20 years. The United States was the mos...
The United States has been the most productive and influential country on H. pylori research, and H. pylori-related research remains an active research field. The relationship between H. pylori infect...